8-K: Monopar Reports Strong 2025, ALXN1840 NDA on Track

Monopar Therapeutics announced its fourth quarter and full-year 2025 financial results, highlighting significant progress for its ALXN1840 Wilson disease program and a strengthened balance sheet.

Summary

• Monopar Therapeutics reported a productive 2025, marked by multiple ALXN1840 data presentations, an important publication, a strengthened balance sheet, and continued progress toward a planned New Drug Application (NDA) submission for ALXN1840 in Wilson disease.
• The company plans to submit an NDA for ALXN1840, a treatment for Wilson disease, to the U.S. Food and Drug Administration (FDA) in mid-2026.
• ALXN1840 data presented at EASL 2025 showed pooled long-term efficacy and safety (n=255; median treatment duration 2.63 years) with a favorable safety profile (n=266).
• Data presented at ANA 2025 demonstrated long-term neurological benefit for ALXN1840, earning an Abstract of Distinction.
• A publication in Journal of Hepatology / AASLD 2025 reported statistically significant improvement in copper balance, driven by increased fecal copper excretion, for ALXN1840.
• Monopar participated in an externally led patient-focused drug development (EL-PFDD) meeting with the FDA on January 29, 2026, for ALXN1840.
• Upcoming 2026 presentations for ALXN1840 include an oral presentation at EASL 2026 and a late-breaking oral and poster presentation at AAN 2026.
• The MNPR-101 radiopharmaceutical programs (MNPR-101-Zr, MNPR-101-Lu, MNPR-101-Ac) targeting uPAR in aggressive cancers are progressing, with ongoing Phase 1 clinical activity in Australia for MNPR-101-Zr and MNPR-101-Lu.
• Investigational New Drug (IND) clearance was received for MNPR-101-Lu to initiate a Phase 1 clinical trial in the US, and an FDA-authorized physician-sponsored Expanded Access Program is active at EDNOC in Houston, Texas.
• Preclinical development of MNPR-101-Ac is ongoing.
• In 2025, Monopar completed an underwritten public offering, generating approximately $91.9 million after a concurrent repurchase of common stock but before offering expenses.
• Cash, cash equivalents, and short-term investments totaled $140.4 million as of December 31, 2025.
• Current funds are expected to support operations through at least December 31, 2027, covering ALXN1840 regulatory and potential commercial activities, MNPR-101 program development, and internal R&D.
• Net loss for Q4 2025 was $5.2 million ($0.61 per share), a decrease from $10.9 million ($2.23 per share) in Q4 2024.
• Net loss for the full year 2025 was $13.7 million ($1.85 per share), down from $15.6 million ($4.11 per share) in 2024.
• Research and Development (R&D) expenses decreased to $3.9 million in Q4 2025 from $9.9 million in Q4 2024, and to $9.9 million for FY 2025 from $13.0 million in FY 2024, primarily due to the absence of one-time ALXN1840 in-licensing expenses in 2024.
• General and Administrative (G&A) expenses increased to $2.2 million in Q4 2025 from $1.2 million in Q4 2024, and to $6.8 million for FY 2025 from $3.2 million in FY 2024, mainly due to higher Board and G&A personnel expenses, stock-based compensation, bonuses, and patent legal fees.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, reflecting strong financial health with an extended cash runway and significant clinical and regulatory progress for its lead asset, ALXN1840, towards an NDA submission. The reduction in net loss and expansion of the leadership team further bolster confidence.

Positives

• Net loss significantly decreased in both Q4 2025 ($5.2M vs $10.9M in Q4 2024) and FY 2025 ($13.7M vs $15.6M in FY 2024).
• Cash, cash equivalents, and short-term investments are strong at $140.4 million as of December 31, 2025.
• The company has extended its cash runway, expecting current funds to support operations through at least December 31, 2027.
• Significant progress has been made towards the ALXN1840 NDA submission for Wilson disease, planned for mid-2026.
• ALXN1840 demonstrated positive long-term efficacy, safety, neurological benefit, and improved copper balance in various presentations and publications.
• An underwritten public offering in 2025 successfully generated approximately $91.9 million, strengthening the balance sheet.
• IND clearance was received for MNPR-101-Lu to initiate a Phase 1 clinical trial in the US, expanding the radiopharmaceutical program's reach.
• An FDA-authorized physician-sponsored Expanded Access Program is in place for MNPR-101, indicating clinical utility and patient need.
• The leadership team was strengthened with the addition of Susan Rodriguez as Chief Commercial and Strategy Officer, preparing for potential ALXN1840 launch.

Negatives

• General and Administrative (G&A) expenses increased substantially in Q4 2025 ($2.2M vs $1.2M in Q4 2024) and FY 2025 ($6.8M vs $3.2M in FY 2024), driven by personnel costs, stock-based compensation, and legal fees.
• Despite reductions, the company continues to report a net loss, which is typical for a clinical-stage biopharmaceutical company but still represents ongoing cash burn.

Risks

• Uncertainties exist regarding the regulatory process for ALXN1840, including the NDA submission to the FDA and its ultimate outcome.
• The rate of market acceptance and competitiveness in terms of pricing, efficacy, and safety for any approved products, especially against larger pharmaceutical firms, is a risk.
• The company's ability to raise sufficient additional funds in the future to support continued preclinical, clinical, regulatory, precommercial, and commercial development, as well as contractual milestone payments, remains a challenge.
• Significant general risks and uncertainties are inherent in the research, development, regulatory approval, and commercialization of imaging agents and therapeutics.

Future Outlook

Monopar plans to submit a New Drug Application (NDA) for ALXN1840 in Wilson disease to the FDA in mid-2026 and is preparing for its potential launch. The company expects its current funds to support operations through at least December 31, 2027, covering regulatory, potential commercial activities for ALXN1840, continued development of MNPR-101 programs, and internal research and development. Further ALXN1840 data presentations are scheduled for EASL 2026 and the American Academy of Neurology (AAN) 2026 Annual Meeting.

Management Comments

• Chandler Robinson, MD, Chief Executive Officer, stated: "2025 was a productive year for Monopar, marked by multiple ALXN1840 data presentations, an important publication, a strengthened balance sheet and continued progress toward a planned New Drug Application submission for ALXN1840 in Wilson disease."
• Dr. Robinson also noted: "We also recently strengthened our leadership team with the addition of Susan Rodriguez as Chief Commercial and Strategy Officer as we prepare for the potential launch of ALXN1840."
• Dr. Robinson expressed gratitude: "We are grateful to the Wilson disease patients and their families whose experiences have informed our efforts to advance ALXN1840."

Industry Context

StockSavvy.ai notes that Monopar Therapeutics operates in the high-risk, high-reward biopharmaceutical sector, focusing on rare genetic disorders like Wilson disease and aggressive cancers. The progress of ALXN1840, with its novel albumin tripartite complex (ATC) activator mechanism, positions it as a potential differentiated therapy in the Wilson disease market, which currently relies on first-line therapies. The advancement of its MNPR-101 radiopharmaceutical platform targeting uPAR also places it in the competitive and evolving field of oncology, particularly in areas like triple-negative breast, colorectal, and pancreatic cancers where unmet needs remain significant.

Management Changes

Stakeholder Impact

• Shareholders: Benefit from a strengthened balance sheet, extended cash runway, reduced net loss, and significant progress on key pipeline assets, potentially increasing long-term value.
• Patients with Wilson disease: Stand to benefit from the accelerated progress towards a new treatment option (ALXN1840) and the company's engagement in patient-focused drug development.
• Employees: The increase in R&D and G&A personnel expenses suggests growth and investment in human capital, potentially leading to more opportunities.
• Regulatory Authorities (FDA): Engaged through EL-PFDD meetings and upcoming NDA submission, indicating active collaboration and adherence to regulatory pathways.

Next Steps

• Submit a New Drug Application (NDA) for ALXN1840 in Wilson disease to the FDA in mid-2026.
• Prepare for the potential commercial launch of ALXN1840.
• Continue development of MNPR-101 radiopharmaceutical programs.
• Conduct internal research and development activities.
• Present ALXN1840 data at EASL 2026, including an oral presentation on tiomolybdate choline's impact on liver disease and neurological symptoms.
• Present ALXN1840 data at the American Academy of Neurology (AAN) 2026 Annual Meeting, including a late-breaking oral and poster presentation on clinical benefit versus standard-of-care in neurologic Wilson disease patients.

Key Dates

Recommendation

Monopar Therapeutics presents a compelling investment case for investors with a moderate to high-risk tolerance. The significant reduction in net loss, coupled with a robust cash position of $140.4 million and an extended cash runway through at least December 31, 2027, provides substantial financial stability. Crucially, the lead asset, ALXN1840, is on track for an NDA submission in mid-2026 for Wilson disease, supported by strong clinical data. This clear regulatory pathway for a rare disease drug, combined with the advancement of the MNPR-101 oncology pipeline and a strengthened leadership team, suggests strong potential for future value creation. While G&A expenses increased, the overall financial and clinical trajectory is highly positive, warranting a 'buy' recommendation for long-term growth.

Keywords

Monopar Therapeutics, MNPR, Wilson disease, ALXN1840, NDA submission, biopharmaceutical, clinical-stage, radiopharmaceutical, MNPR-101, cancer treatment, financial results, cash runway, FDA, R&D expenses, net loss, public offering